Table 1.
Characteristics among 2,546 prostate cancer cases (1982–2007), by baseline BMI
| 18.6 – 24.9 | BMI (kg/m2) 25.0 – 29.9 | 30.0–36.1 | P value | |
|---|---|---|---|---|
| All prostate cancer (%) | 1470 (57.7) | 989 (38.8) | 87 (3.4) | |
| Pre-PSA era (1982–1990, %) | 237 (57.1) | 165 (39.8) | 13 (3.1) | |
| PSA era (1991–2007, %) | 1233 (57.9) | 824 (38.7) | 74 (3.5) | 0.88 |
| Deaths due to prostate cancer (%) | 134 (9.1) | 129 (13.0) | 18 (20.7) | 0.0001 |
| Overall follow-up, median (min, max, yr) | ||||
| Baseline to diagnosis | 14.3 (0.0, 23.9) | 14.0 (0.2, 23.8) | 13.1 (0.5, 23.0) | |
| Diagnosis to end of follow-up | 7.5 (0.0, 22.7) | 7.3 (0.1, 24.3) | 6.2 (0.5, 17.4) | |
| Age at baseline (yr) | 56.7± 9.3 | 57.2 ± 8.4 | 55.9 ± 7.5 | 0.31 |
| Age at diagnosis (yr) | 70.6 ± 7.7 | 70.8 ± 7.2 | 69.2 ± 6.7 | 0.13 |
| Smoking status at baseline (%) | ||||
| Non-smoker | 774 (52.7) | 464 (46.9) | 35 (40.2) | 0.02 |
| Past smoker | 572 (38.9) | 421 (42.6) | 42 (48.3) | |
| Current smoker | 124 (8.4) | 104 (10.5) | 10 (11.5) | |
| Baseline diabetes (%) | 23 (1.6) | 15 (1.5) | 0 (0.0) | 0.50 |
| Clinical Stage, N (%)a | ||||
| T1/T2 | 1141 (89.8) | 767 (90.0) | 58 (78.4) | 0.0010 |
| T3/T4 | 87 (6.9) | 48 (5.6) | 7 (9.5) | |
| N1/M1 | 42 (3.3) | 37 (4.3) | 9 (12.2) | |
| Clinical Stage, N (%) Unknown | 200 | 137 | 13 | |
| Gleason score, N (%) a | ||||
| 2–6 | 897 (63.1) | 569 (59.6) | 49 (60.5) | |
| 7 | 343 (24.1) | 269 (28.2) | 16 (19.8) | 0.06 |
| 8–10 | 182 (12.8) | 117 (12.3) | 16 (19.8) | |
| Gleason score, N (%) Unknown | 48 | 34 | 6 | |
| Baseline PSA, ng/mL, N, (%) b | ||||
| 4 – 9.9 | 87 (20.8) | 62 (22.4) | 6 (27.3) | 0.71 |
| ≥ 10 | 63 (15) | 46 (16.6) | 5 (22.7) | 0.58 |
| PSA at diagnosis, ng/mL, N (%) b | ||||
| 4 – 9.9 | 580 (53.2) | 421 (58.3) | 30 (52.6) | 0.09 |
| ≥ 10 | 375 (34.4) | 224 (31.0) | 22 (38.6) | 0.22 |
| Plasma C-peptide concentrations (ng/mL), median (10th–90th percentile) b | 1.5 (0.7–3.9) | 1.9 (0.8–4.5) | 2.8 (1.4–4.7) | <0.0001 |
a
Among the 2,546 men, 350 (14%) had unknown stage and 88 (3%) had unknown Gleason grade information.
b
Baseline plasma PSA concentration were available for 718 men; data for PSA at diagnosis were available for 1869 men; and baseline plasma C-peptide concentrations were available for 827 men.